Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
MAP Pharmaceuticals, Inc. (MAPP)
|
Add to portfolio |
|
|
|
| Price: |
$15.73
| | Metrics |
| OS: |
35.3
|
M
| |
|
|
| Market cap: |
$555
|
M
| |
|
|
|
Net cash:
|
$114
|
M
| |
$3.24
|
per share
|
|
EV:
|
$441
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-11 | Jul-03-11 | Dec-31-10 | Jul-03-10 | Dec-31-09 | Jul-03-09 | Dec-31-08 | Jul-03-08 |
| Revenues | 23.1 | 251.1 | 37.8 | 217.5 | 54.2 | 179.7 | 59.3 | 131.7 |
| Revenue growth | -38.9% | 15.5% | -30.3% | 21.0% | -8.6% | 36.4% | 89.0% | 81.9% |
| Cost of goods sold | 0.0 | 85.0 | 15.7 | 163.3 | 0.0 | 125.5 | 59.3 | 131.7 |
| Gross profit | 23.1 | 166.2 | 22.1 | 54.2 | 54.2 | 54.2 | 0.0 | 0.0 |
| Gross margin | 100.0% | 66.2% | 58.4% | 24.9% | 100.0% | 30.1% | 0.0% | 0.0% |
| Selling, general and administrative | 22.1 | 85.0 | 15.7 | 62.9 | 13.1 | 47.2 | 13.4 | 34.1 |
| Research and development | 33.7 | | | | 48.0 | | | |
| EBIT | -32.7 | -258.9 | -53.5 | -226.2 | -7.0 | -172.7 | -72.7 | -165.8 |
| EBIT margin | -141.5% | -103.1% | -141.6% | -104.0% | -12.9% | -96.1% | -122.6% | -125.9% |
| Pre-tax income | -32.9 | -260.5 | -54.7 | -227.5 | -9.0 | -172.9 | -72.9 | -163.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -32.9 | -260.5 | -54.7 | -227.5 | -9.0 | -172.9 | -72.9 | -163.9 |
| Net margin | -142.8% | -103.7% | -144.7% | -104.6% | -16.6% | -96.2% | -123.0% | -124.4% |
| |
| Diluted EPS | ($1.08) | | ($2.05) | | ($0.41) | | | |
| Shares outstanding (diluted) | 30.4 | | 26.6 | | 22.2 | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|